Trials / Terminated
TerminatedNCT02100150
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Neuren Pharmaceuticals Limited · Industry
- Sex
- All
- Age
- 16 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.
Detailed description
Traumatic brain injury (TBI) is an injury to the head caused by an external trauma that can lead to brain cell death, inflammation, edema, hemorrhage, and disruption of normal brain cell function. mTBI frequently results in persistent functional impairment including problems with cognitive function, memory, mood, and other personality disorders. There are currently no drugs available to reduce the brain damage or sequelae that result from TBI. Clearly, a safe and effective treatment for concussion injury and all forms of TBI would be an important development for military personnel as well as the general population. This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescents and adults with mTBI. The study also will also investigate measures of efficacy during treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNZ-2566 | Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection. |
| DRUG | Placebo | Strawberry flavored solution 0.5% v/v in Water for Injection |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2014-03-31
- Last updated
- 2018-02-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02100150. Inclusion in this directory is not an endorsement.